This invention relates to substituted pyrimidinone and pyrimidithione
derivatives that bind with high affifnity to CRF.sub.1 receptors,
including human CRF.sub.1 receptors. This invention also relates to
methods of using the compounds of the invention to treat a disorder or
condition, the treatment of which can be effected or facilitated by
antagonizing a CRF receptor, such as CNS disorders or diseases,
particularly anxiety disorders, and depression and stress related
disorders.